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Am J Physiol Renal Physiol 306: F130–F137, 2014. First published
November 6, 2013; doi:10.1152/ajprenal.00114.2013.—Although the
kidney is believed to play a minor role in bile acid (BA) excretion,
chronic renal failure (CRF) has been reported to be associated with
increased serum bile acid levels and alterations in BA homeostasis.
The mechanisms for elevated BA levels are poorly understood in both
clinical and experimental studies. This study was designed to examine
the effects of naturally progressing CRF of longer duration on the
hepatic and renal mRNA and protein levels of the BA-synthesizing
enzyme Cyp7a1 and the BA transporters Ntcp, Bsep, Mrp3, Ost-,
and Ost-. Sprague-Dawley rats were randomized to the CRF group
(5⁄6 nephrectomy) or to the sham-operated control group and were
analyzed 8 wk after surgery. Results obtained in the CRF rats were
compared with those obtained in rats that had undergone uninephrec-
tomy (UNX). The CRF group exhibited signiﬁcantly increased plasma
cholesterol and BA concentrations. Hepatic Cyp7a1 mRNA and
protein levels were almost identical in the two groups. Hepatic Mrp3,
Ost-, and Ost- expression was increased, suggesting increased
basolateral efﬂux of bile acids into the blood. However, no such
changes in BA transporter expression were observed in the remnant
kidney. In UNX rats, similar changes in plasma BA levels and in the
expression of BA transporters were found. We hypothesize that the
increase in plasma BA is an early event in the progression of CRF and
is caused by increased efﬂux across the basolateral hepatocyte mem-
brane.
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THE KIDNEY IS ONE OF THE MAJOR organs involved in whole-body
homeostasis, with its major functions being the excretion of
waste metabolites, regulation of blood pressure and lipid me-
tabolism, secretion and degradation of hormones, and the
production and utilization of systemic glucose (16, 22, 30). It
is well known that chronic renal impairment is further com-
plicated by high blood pressure (3), deranged carbohydrate
metabolism (21), and dyslipidemia (5). Moreover, chronic
renal failure (CRF) has been reported to be associated with
increased serum bile acid levels and alterations in the bile acid
balance (14).
Primary bile acids are synthesized from cholesterol by hepa-
tocytes (12, 36). They are secreted into bile and play important
roles in the emulsion, digestion, and absorption of dietary fat
and liposoluble vitamins. Except for a small fraction of bile
acids constituting5% of the whole pool that is lost every day
in the feces, the remaining bile acids that reach the intestine are
actively reabsorbed toward the portal blood, mainly by the
ileum (39). The ﬂux of bile acid molecules through hepato-
cytes plays an important role in controlling, at the transcrip-
tional level, the rate of metabolic pathways responsible for
de novo biosynthesis of the additional bile acids necessary
to compensate for fecal loss (25). Although it has tradition-
ally been thought that ﬁltration, reabsorption, and secretion
by the kidney play a minor role in bile acid homeostasis in
healthy humans, urinary output of sulfated bile acids be-
comes an important excretion route under cholestatic con-
ditions (9, 37).
Several studies have reported that hepatic Cyp7a1 activity,
the rate-limiting enzyme in bile acid synthesis, is virtually
identical in rats with CRF and normal control animals (19, 34).
Moreover, an unchanged rate of bile acid production was also
demonstrated (19, 26), indicating normal hepatic de novo
synthesis of bile acids in CRF. However, these studies did not
evaluate expression of bile acid transporters. Thus, they could
not explain the occurrence of elevated serum bile acid levels in
CRF. The present study was therefore undertaken to determine
the mechanism underlying the increased bile acid levels in
CRF. The expression of hepatic Cyp7a1 and of both hepatic
and renal bile salt transporters (e.g., Ntcp, Slco1a1, Bsep,
Mrp3, Mrp4, Ost- and Ost-) was compared in CRF and
sham-operated control animals (with free access to regular rat
chow). Furthermore, an additional uninephrectomized rat
group was examined to study the impact of renal function on
bile acid metabolism and transport.
METHODS
Animal models. Male Sprague-Dawley rats weighing 180–200 g
were randomly assigned to the CRF and sham-operated normal
control groups. Another group of male Sprague-Dawley rats weighing
180–200 g were randomly assigned to the UNX or sham-operated
normal control groups. Rats from each group were housed in a
climate-controlled, light-regulated facility with a 12:12-h day-night
cycle. The animals were fed regular rat chow and received water ad
libitum. The animals assigned to the renal surgery groups underwent
a 5⁄6 nephrectomy or a uninephrectomy by surgical resection using a
ﬂank incision to expose the kidney retroperitoneally as described
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elsewhere (42). Sham-operated animals underwent the same incision
and kidney exposure, but the kidney was left intact. A minimum of
eight animals was used in each group. Plasma total cholesterol and
creatinine concentrations were measured using a synchro CX3 auto-
analyzer (Beckman Instruments). Plasma total bile acids were mea-
sured using a kit from Crystal Chemistry, and individual bile acid
species were quantitated by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) (27). Urinary protein concentrations were
determined using a kit from Wako Chemical Industries (Tokyo,
Japan). All experiments were approved by the local institutional
animal committee.
Isolation of primary proximal tubule cells. Primary proximal tubule
cells were isolated from kidneys of Sprague-Dawley rats as described
previously (6). Brieﬂy, kidney cortices from rats (weighing 180–200
g) were dissected, sliced, minced, and digested in 0.25% trypsin
solution (Life Technologies BRL, Grand Island, NY) in a shaking
incubator at 37°C for 1 h. Trypsin was neutralized with growth
medium (DMEM and 10% FBS containing 100 U/ml penicillin and
0.1 mg/ml streptomycin). The suspension was pipetted and was
passed through a 100-m cell strainer (BectonDickinson Labware,
Franklin Lakes, NJ). The samples were centrifuged (600 rpm for 5
min) to pellet the tubules, washed with 10 ml of medium, centrifuged,
and washed twice more. The ﬁnal pellet, consisting mostly of renal
tubules, was resuspended in culture medium (REBM bullet kit,
Clonetics), plated onto culture dishes (Nalge Nunc, Naperville, IL),
and incubated at 37°C in a CO2 incubator with medium changes every
2 days until conﬂuent. Experiments were carried out in serum-free
DMEM. Cells were incubated by the addition of 100 M chenode-
oxycholic acid or 1 M GW4064 (Sigma-Aldrich, St. Louis, MO) for
24 h. Total RNA was extracted by the method described below.
Isolation of liver and kidney RNA and quantiﬁcation of transcript
levels. The rats were killed 8 wk after surgery. The liver and kidney
were removed immediately, snap frozen in liquid nitrogen, and stored
at 80°C. Total RNA was prepared using TRIzol (Invitrogen). The
amount of mRNA was determined from the absorbance at 260 nm.
After DNAse treatment (Promega), 2 g total RNA was reverse
transcribed using oligo-dT priming and SuperscriptII (Invitrogen).
First-strand complementary DNA was used as the template for real-
time polymerase chain reaction analysis with TaqMan master mix and
primers (Applied Biosystems). Transcript levels, determined in two
independent complementary DNA preparations, were calculated as
described and expressed relative to the GAPDH housekeeping gene.
All of the results are expressed as means  SE. Unpaired t-tests were
used for statistical comparisons.
Western blotting. Lysates (20 g protein) from liver, ileum, or
kidney tissue were separated by SDS-PAGE and blotted on polyvi-
nylidene diﬂuoride membranes (Millipore, Billerica, MA). The mem-
branes were blocked with TBS containing 0.1% Tween 20 and 3%
BSA for 1 h at room temperature and incubated overnight at 4°C with
the respective antibodies. Subsequently, the blots were washed with
TBS containing 0.1% Tween 20, treated with horseradish-peroxidase-
conjugated secondary antibodies at room temperature for 1 h, and
developed using the ECL Plus detection system (Amersham Bioscience,
Buckinghamshire, UK). Antibodies against Bsep, Ntcp, Slco1a1, Mrp2,
and Mrp3 were previously generated in our group (Dr. Bruno Stieger);
anti-Cyp7a1 was from Biorbyt, anti-Ost, and anti-Asbt (Santa Cruz
Biotechnology, Santa Cruz, CA).
RESULTS
Plasma bile acid concentrations in CRF rats. The effect of
CRF on plasma cholesterol, creatinine, creatinine clearance,
urinary protein, and body weight is shown in Table 1. As
expected, the CRF group exhibited a signiﬁcant increase in
plasma creatinine concentration and a signiﬁcant decrease in
creatinine clearance and body weight compared with the nor-
mal control group. In addition, the CRF group exhibited mild
proteinuria and a signiﬁcant rise in total cholesterol relative to
that found in the control group. In parallel, the plasma total bile
acid concentration was signiﬁcantly higher in the CRF group
(P  0.01, Fig.1A), consistent with other reports (11, 14). The
increase in plasma bile acids as determined with the enzymatic
assay was conﬁrmed by LC-MS/MS analysis of individual bile
acid species, which showed about a twofold increase in the
concentration of individual bile acids measured, notably un-
conjugated bile acids (Supplementary Table S1; all supplemen-
tary material for this article is accessible on the journal web-
site.). Concentrations of almost all bile acids were increased in
CRF rats, including cholic acid, chenodeoxycholic acid,
muricholic acid, and hyodeoxycholic acid. However, the per-
centage of 6-hydroxylated bile acids (muricholic acid and
hyodeoxycholic acid) did not differ between groups.
Effect of CRF on expression of bile acid transporters in the
liver, intestine, and kidney. In view of the increase in serum
bile acids, we studied the expression of hepatic Cyp7a1, the
rate-limiting step in bile acid synthesis. As shown in Fig. 1, C
and D, expression of Cyp7a1 did not differ between the two
groups at the mRNA and protein levels. Moreover, mRNA
expression of Cyp8b1, an enzyme involved in the synthesis of
cholic acid, was almost identical in the CRF group and control
animals (Fig. 1B). These results indicate that the increase in
plasma bile acids does not result from a higher synthesis rate of
bile acids.
In CRF rats, both mRNA and protein expression of the
basolateral uptake transporters Ntcp and Slco1a1 did not differ
compared with controls. In contrast, mRNA levels of Mrp3,
Ost-, and Ost-, the basolateral bile acid efﬂux transporters,
were increased (Fig. 2A). Western blots conﬁrmed higher
expression of Mrp3 and Ost- (Fig. 2B) in CRF rats at the
protein level. However, mRNA expression of Bsep and Mrp2,
the canalicular efﬂux pumps, was almost the same as in the
sham group. Since Mrp3, Ost-, and Ost- are target genes of
Fxr (43), a nuclear receptor that is activated by bile acids, we
compared Fxr and its downstream target gene Shp in CRF and
control groups. As shown in Fig. 2C, mRNA levels of Fxr and
Shp did not differ between groups. Shp expression in CRF rats
was consistent with that of Cyp7a1, indicating that elevated
plasma bile acids do not negatively regulate bile acid synthesis
in CRF.
mRNA and protein levels of bile acid transporters from
ileum and the remaining kidney of CRF rats were examined
and compared with the control animals. In contrast to the
changes in bile acid transporter expression found in the liver,
there were no signiﬁcant changes in bile acid transporters both
Table 1. Effect of CRF on plasma concentrations of
cholesterol, creatinine, creatinine clearance (Ccr), urinary
protein, and body weight
Sham (n 	 8) CRF (n 	 8) P Value
Total cholesterol, mg/dl 59.8 5.4 142.5  16.4 0.01
Creatinine, ml/dl 0.54 0.02 1.31  0.16 0.01
Ccr, ml/24 h 1.9  0.08 0.6  0.11 0.01
Urine protein, mg/24 h 9.2 1.2 39.2  3.4 0.01
Body weight, g 433.5  6.9 386.4  7.7 0.01
Values are means  SE; n 	 8/group. Sham, sham-operated control; CRF,
chronic renal failure; Ccr, creatinine clearance.
2
ht
tp
://
do
c.
re
ro
.c
h
in the ileum and the remaining 1/6 kidneys of the CRF group
(Fig. 3). Fxr and Shp levels in the kidney were also checked in
both groups. Almost identical Fxr and Shp mRNA levels were
found in the CRF group, indicating that the Fxr signaling
pathway was not activated in the remaining kidney.
Effect of FXR agonists on expression of FXR target genes in
proximal tubule cells from the kidney. In view of the apparent
difference between the liver and kidney in the changes in bile
acid transporter expression induced by CRF, we next investi-
gated whether Fxr signaling is conserved in rat kidney. As Fxr
is expressed in kidney proximal tubules (23) and many Fxr
target genes are also located there (43), we aimed to exclude an
absence of intact Fxr signaling in the kidney as an explanation
for the lack of effect of CRF on renal bile acid transporter
expression. To demonstrate this, we cultured kidney proximal
tubule cells from rats and incubated cells with CDCA or
GW4064, two Fxr agonists that activate Fxr signaling. Signif-
icant increases in Shp and Mrp2 mRNAs, two known Fxr
target genes in the kidney (8, 15), were observed in proximal
tubule cells incubated with CDCA or GW4064 for 24 h.
Meanwhile, the Fxr mRNA expression level did not change
(Fig. 4). Furthermore, mRNA levels of bile acid transporters
Ost-/ were signiﬁcantly higher, and the Slco1a1 mRNA
level was decreased after CDCA and GW4064 treatment (Fig.
4). Taken together, these data suggest that the Fxr signaling
pathway is conserved in the kidney and that an activation of
Fxr would be expected to inﬂuence the expression of bile acid
transporters in renal proximal tubule cells.
Effect of UNX on bile acid transporters in the liver and
kidney. Finally, we employed UNX as a model to further assess
whether the change in bile acid levels was correlated with
kidney function, since UNX rats did not show any renal failure
at 8 wk after surgery. As shown in Fig. 5A, increased plasma
bile acid levels were also observed in UNX rats, with no
marked changes in Cyp7a1 compared with the control group
(Fig. 5C). Furthermore, hepatic basolateral bile acid transport-
ers Ost-/ were increased at the mRNA level (Fig. 5B).
However, analysis of the renal expression of bile acid trans-
porters in the remnant kidney again showed no differences
between the two groups (Fig. 5D).
DISCUSSION
This study shows that plasma bile acid levels are increased
in rats with CRF induced by 5⁄6 subtotal nephrectomy. We
observed increased expression of hepatic basolateral bile acid
efﬂux transporters Mrp3, Ost-, and Ost- in CRF rats, but no
such changes in bile acid transporter expression were ob-
served in ileum and the remnant kidney. Although the
expression of Mrp3 and Ost-/ is low in rodent liver, their
mRNA levels were strongly increased in the liver of CRF
rats, with no change in Shp and bile acid-synthesizing
enzymes. Furthermore, similar changes in plasma bile acids
and expression levels of bile acid transporters were detected
in rats with UNX, a relatively mild animal model of renal
dysfunction. These results suggest that changes in hepatic
bile acid homeostasis are an early event in the progression
of CRF, and increased plasma bile acid levels may result
from an increased efﬂux of bile acids across the basolateral
hepatocyte membrane (Fig. 6).
An important ﬁnding in this study was the increase in plasma
bile acid concentrations in CRF, which is consistent with
previous clinical reports by Jimenez et al. (14). Despite ele-
vated bile acid levels, Cyp7a1, the rate-limiting de novo bile
acid-synthesizing enzyme, was not repressed at either the
mRNA level or the protein level. Another rate-limiting
enzyme involved in the synthesis of cholic acid, Cyp8b1,
also remained at normal levels. These results are in line with
the absence of increased Shp mRNA expression in CRF rats,
suggesting that Fxr was not activated. Furthermore, the
expression of Fxr, which acts in concert with Shp to sup-
press bile acid-synthesizing enzymes, did not differ from the
controls. Thus the contribution of the Fxr-Shp pathway to
the increase in plasma bile acid levels appears to be minor,
Fig. 1. Effect of chronic renal failure (CRF)
on total serum bile acid levels and bile acid-
synthesizing enzymes in the liver. A: plasma
total bile acid levels in control (sham) rats
and rats with CRF. B and C: comparisons of
hepatic Cyp8b1 mRNA (B) and Cyp7a1
mRNA (C) levels between sham and CRF
groups. Values are means  SE; n 	
8/group. D: representative Western blot of
Cyp7a1 in liver tissue of sham and CRF
groups. Samples from rat ileum were used as
a negative control.
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which also explains the lack of negative feedback regulation
on de novo bile acid production. The increase in serum bile
acids is most probably attributable to the increased expres-
sion of Ost-/ and Mrp3. Normally, these genes are ex-
pressed at low levels in hepatocytes, and we hypothesize
that their induction could shuttle the transport of bile acids
back into sinusoidal blood (43). However, the extent to
which induction of Ost-/ and Mrp3 translates into a true
increase in the basolateral efﬂux of bile acids remains to be
elucidated in functional studies.
It is unclear whether the changes in bile acid transporter
expression represent a secondary compensatory response to the
changes in renal function induced by CRF or UNX. Increased
plasma bile acid levels could activate energy expenditure in
adipocytes and reduce macrophage inﬂammation and lipid
loading through TGR5 (28, 29, 38). As a result, the free fatty
acids eluted from adipocytes may redistribute in organs such
as the liver and kidneys (40, 41). Changed bile acid levels
also reﬂect obese and diabetic conditions in both mice and
humans (4, 18). The major efﬂux pump for bile acids out of
the hepatocyte is the bile salt export pump (7), and induction
of Bsep expression may reduce the bile acid load in hepa-
tocytes. The increased expression of Mrp3, Ost-, and
Ost- also provides a mechanism to lower hepatocellular
retention of hydrophobic bile acids and other potentially
toxic compounds that would normally be destined for biliary
excretion. Other studies (10, 17) showed a signiﬁcant in-
crease in liver Mrp3 expression at the mRNA and protein
levels in CRF rats, consistent with our results. Naud et al.
(24) found a signiﬁcant increase in liver Mrp2 at the mRNA
but not the protein level in CRF rats, which is conﬁrmed by
our data.
Very few studies have evaluated the effect of CRF on the
urinary output of bile acids. Clinical studies showed increased
serum bile acids in both CRF and transplant patients; however,
they did not show any change in the urinary output of bile acids
in these patients (14). Data from Zollner et al. (43) suggest that
the upregulation of Ost-/ expression and the increased efﬂux
of bile acids into the blood for renal excretion may exert a
protective effect on hepatocytes and the biliary epithelium in
response to an increased bile acid load (43). Moreover, recent
studies demonstrate that uremic toxins can directly inhibit
transport activities of organic anion transporters OATP1B1,
OATP1B3, and OATP2B1 in hepatocytes (31, 33) and OATs
Fig. 2. Effect of CRF on the expression of bile
acid transporters in the liver. A: comparison of
hepatic bile acid transporter mRNA levels be-
tween sham and CRF groups. B: representative
Western blot of Bsep, Ntcp, Slco1a1, Mrp2,
Mrp3, and Ost- in liver tissue of sham and CRF
groups. C: comparison of hepatic Fxr and Shp
mRNA levels between sham and CRF groups.
Values are means  SE; n 	 8/group. *P 
0.01.
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in the kidney (13). However, further studies should be done to
correlate renal expression of bile acid transporters with the
urinary excretion of bile acids.
Previous studies demonstrated that cholic acid induces the
expression of Ost- and Ost- in the liver and kidneys in
Fxr
/
 but not Fxr/ mice, conﬁrming that Ost-/ are
regulated by Fxr (43). We observed similar changes in Ost-
and Ost- mRNA levels after Fxr activation in proximal tubule
cells of rat kidney (Fig. 4). Nonetheless, in this study, the lack
of parallelism in Ost-/ expression between the liver and
kidneys and the absence of Fxr activation in these two tissues
suggest that the response of basolateral bile acid transporters is
due to other factors. Recent evidence indicates that uremic
toxins and proinﬂammatory cytokines may affect the transcrip-
tion of hepatic transporter genes (1, 32). Naud et al. (24)
showed that uremic serum modiﬁes the expression of hepatic
drug transporters including Mrp3. In human primary hepato-
cytes, TNF-, IL-6, and IL-1, the major proinﬂammatory
cytokines that are increased in CRF, reduce the expression of
NTCP and induce the expression of MRP1 and MRP4 (35).
Moreover, several orphan nuclear receptors, including the
pregnane X receptor and constitutive androstane receptor, are
Fig. 3. Effect of CRF on the expression of bile acid transporters in the kidney and intestine. A: comparison of bile acid transporter mRNA levels in remnant
kidneys of CRF rats and in kidneys from the sham group. Values are means  SE; n 	 8/group. B: representative Western blot of the apical Na
-dependent
bile acid transporter (Asbt), Mrp3, and Ost- in kidney tissue of sham and CRF groups. C: comparison of bile acid transporter mRNA levels in ileum of sham
and CRF rats. D: representative Western blot of Asbt, Mrp3, and Ost- in ileum tissue of sham and CRF groups. Values are means  SE; n 	 8/group. *P 
0.01.
Fig. 4. Effect of FXR agonists on the expres-
sion of bile acid transporters in primary
cultured proximal tubule cells (PTCs) iso-
lated from rat kidney. Shown is a compari-
son of bile acid transporter mRNA levels
and Fxr and Shp mRNA levels in PTCs
treated with DMSO, chenodeoxycholic acid
(CDCA), or GW4064 for 24 h. Values are
means  SE; n 	 3/group. *P  0.01.
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known to regulate the transcription of transporter genes in the
liver of CRF rats (2, 20). However, the exact molecular
mechanism for the increase in expression of Ost- and Ost-
in CRF remains to be elucidated.
In summary, both CRF and uninephrectomy are associ-
ated with an increase in plasma bile acid levels, suggesting
that this is an early event that takes place before kidney
function is impaired. Maintenance of bile acid synthesis and
elevated basolateral Mrp3 and Ost-/ expression may
either be a desired response during chronic renal disease to
raise serum bile acid concentrations, thereby inducing a
signaling effect of bile acids in other tissues, or it may
indicate a protective mechanism of hepatocytes to facilitate
basolateral extrusion of bile acids in response to an as yet
uncharacterized effect of renal failure on hepatocyte bile
acid homeostasis.
Fig. 5. Effect of uninephrectomy (UNX) on
the expression of bile acid transporters in the
liver and kidney. A: plasma total bile acid
levels in sham-operated rats and rats with
UNX. B and C: comparison of hepatic bile
acid transporter mRNA levels and Cyp7a1,
Cyp8b1, Fxr, and Shp mRNA levels be-
tween sham and UNX rats. D: comparison of
bile acid transporter mRNA levels in rem-
nant kidneys of UNX rats and in kidneys of
sham group. Values are means  SE; n 	
8/group. *P  0.01.
Fig. 6. Bile acid transporters expressed in the
plasma membrane of hepatocytes, enterocytes, and
renal proximal tubular cells. Transporters which
efﬂux bile acids are shown in green, and transporters
that mediate the uptake of bile acids are shown in
orange. Bile acids are synthesized and conjugated in
the liver and secreted into the intestine. They are
reabsorbed into the portal circulation in the small
intestine and subsequently return to the liver, where
uptake into hepatocytes occurs by Na
-dependent
(Ntcp) and Na
-independent (Oatps) transporters.
In the kidney, bile acids undergo glomerular ﬁltra-
tion, but are reabsorbed in the proximal renal tubule
by the apical Na
-dependent bile acid transporter
(Asbt).
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